On August 1, Green Leaf Group announced the acquisition of Singapore's genetic sequencing company Vela Diagnostics, which marked the beginning of the green leaf group's involvement in the gene sequencing business and officially entered the precision medicine . It is understood that in recent years, the business of Green Leaf Group has developed rapidly. It started from the professional pharmaceutical field. At present, it has three business segments: Green Leaf Pharmaceutical, Green Leaf Medical and Green Leaf Investment. It has gradually become an international business with investment and industrial development as its core business. The group company, which acquired Vela, hopes that the gene sequencing technology will have synergy with the existing business areas of the group, forming a comprehensive medical service from diagnosis to treatment.
Market potential is growing rapidly
According to the reporter's understanding, Green Leaf Group acquired the Singapore genetic sequencing company Vela Diagnostics, the transaction amount is about 30 million US dollars. In fact, in recent years, in addition to focusing on innovative drug research and development, Green Leaf Group is also focusing on expanding its business in other fields. In 2014, Luye Pharmaceutical was listed in Hong Kong and became the largest pharmaceutical new stock in the Hong Kong Stock Exchange in the past two years. In addition, Green Leaf acquired Nanjing Green Leaf Cisco, which is a market-leading paclitaxel preparation with a broad market prospect. At the same time, Green Leaf will expand its business in the medical field, with a focus on specialist advantages in rehabilitation, women's hospitals, plastic surgery, oral, physical examination, geriatrics and oncology.
Why invest in precision medicine? Figures show that in 2013, the global precision treatment market reached a total value of 4.5 billion US dollars, with a compound annual growth rate of more than 20%, and will reach 11.7 billion US dollars in 2018. China has also increased its support for precision medicine. In January this year, China announced a pilot unit for prenatal screening and diagnosis of high-throughput sequencing. In April, it announced a pilot unit for high-throughput gene sequencing for tumor diagnosis and treatment. The Ministry of Science and Technology held the first national expert meeting on precision medicine strategy and decided to invest 60 billion yuan in the field of precision medicine by 2030, indicating the government's determination to promote the development of precision medicine.
The huge market has stimulated the enthusiasm of enterprises, and companies have advertised to enter this market, while others have expanded their scales to prepare for listing. In July this year, Shanghai Bohao Bio and Shanghai Dongfulong Medical Technology Industry Development Co., Ltd. signed an agreement to raise more than 100 million yuan. This is one of the important measures for the layout of precision medical treatment of Shanghai Dongfulong Technology Co., Ltd. Through the joint efforts of the shareholders of Dongfulong, Bohao Bio and Bohao Bio, we will directly focus on the core areas of precision medicine and jointly open “precise medical treatment, Accurate detection, precise service" pattern.
Advanced technology is the most important
Yan Hongli, director of the Reproductive Medicine Center of Shandong International Biotechnology Park, told the reporter that the acquisition of Vela is worthy of its advanced technology. According to him, Vela Diagnostics was founded in 2011 as a global provider of integrated molecular diagnostic workflow solutions. Vela Diagnostics provides real-time fluorescence real-time quantitative polymerase chain reaction (Real-Time PCR) and next-generation sequencing (NGS, Next-Generation Sequencing) provides an automated platform for disease molecular diagnostic workflows, providing customers with comprehensive solutions for equipment, reagents and data processing. It has operations in the United States, the European Union, Australia and other countries and regions. In the field of PCR and NGS-based molecular diagnostics, Vela Diagnostics has achieved industry leadership with 27 EU and 19 Australian certifications.
At present, there are many genetic sequencing companies in China, but most of them are small in scale and different in technical means. The most famous are the Huada Gene in Shenzhen, the National Human Genome North Center and the National Human Genome South Center. Based on these two research centers, several different genetic testing companies have been established.
In the same sample, the test reports given by several genetic tests are not the same, and the accuracy of genetic testing is questionable. Zhou Yujuan, Marketing Department of Beijing Nosai Gene Company, told the reporter that the detection accuracy is related to two aspects. First, the accuracy of the test data, which requires strict testing procedures and quality control standards to ensure; second, the accuracy of the results analysis and interpretation. Sex, based on evidence-based medicine and a large sample database. According to the reporter's understanding, many genetic testing companies in China still lack technology and research in this area.
Yan Hongli told reporters, "It is not excluded to cooperate with domestic genetic testing companies or to acquire domestic related companies. Technology leadership is our first consideration."
For clinical and pharmaceutical development
According to the reporter's understanding, a genetic testing company appeared in China a dozen years ago. The genetic testing industry is mainly based on personalized medical testing, but in recent years, its contribution to "precise medical care" has become more and more important. In many targeted drugs, cancers, and hereditary diseases, there is a huge market for genetic testing, and it is profitable.
When genetic testing just appeared on the market, they used paternity testing, individualized disease detection, and children's natural genetic testing as the most important direction for the public, and most companies adopted the method of outsourcing business, the level of genetic testing in the market. Good and bad.
In recent years, genetic testing has become more and more widely used in clinical practice. It has more and more clinically combined prenatal screening and targeted drug applications for treating tumors, and has high profits. It is a precise medical treatment for drug development and clinical diagnosis. The direction of development. According to the reporter, Green Leaf Group will use its own advantages, and its precision medical treatment will develop in the direction of clinical and pharmaceutical.
Industry insiders analyzed that China's gene sequencing technology is not behind. China has participated in the International Human Genome Project and has undertaken 1% of the sequencing tasks. To this end, the National Human Genome North Center and the National Human Genome South Center have been established. These institutions have undertaken major scientific research tasks in the national life sciences and genomes. Excellent genetic testing talents, mastering the most advanced genetic testing technology in the world. However, these gene sequencing organizations with strong backgrounds often tend to carry out scientific research, are not good at marketization of genetic testing, and cannot take the lead in promoting the rapid development of the industry. The strength of enterprises is good at grasping business opportunities, and their participation will accelerate China. The development of the genetic testing industry.
Precision medicine has been incorporated into the strategy of some pharmaceutical companies, and the future will certainly accelerate the development of diagnostic technology and diagnostic industry in China. The genetic testing industry is a vital part of the future individualized medical and big data health industry. The market will explode in the future, and large enterprises at home and abroad have begun to lay out.
Energy Mints,Viter Energy Mints,Rally Energy Mints,Nootropic Mints
Soar Biotech Co.,Ltd , https://www.xylitgum.com